A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. - Test2 - elhamkhani - TriplyDB

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

http://www.wikidata.org/entity/Q36657509

about

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation Activin A inhibits RANKL-mediated osteoclast formation, movement and function in murine bone marrow macrophage cultures.Bone morphogenetic protein-3b (BMP-3b) is expressed in adipocytes and inhibits adipogenesis as a unique complex Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease Update in new anabolic therapies for osteoporosis Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer The effects of GATA-1 and NF-E2 deficiency on bone biomechanical, biochemical, and mineral properties.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics Growth factor control of bone mass.A roadmap to the brittle bones of cystic fibrosis.An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin Sotatercept in patients with osteolytic lesions of multiple myeloma.Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.Development of novel activin-targeted therapeutics.Loss of BMPR2 leads to high bone mass due to increased osteoblast activity Bone anabolic agents for the treatment of multiple myeloma.BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives New treatment modalities in osteoporosis.Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing.A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength.Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.Virtual High-Throughput Screening To Identify Novel Activin Antagonists.Impact of Gap Junctional Intercellular Communication on MLO-Y4 Sclerostin and Soluble Factor Expression.Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells Cellular mechanisms of multiple myeloma bone disease Bone and skeletal muscle: neighbors with close ties Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.Activin signaling as an emerging target for therapeutic interventions Reproductive hormones in breast cancer bone metastasis: The role of inhibins.Development of insulin-producing cells from primitive biologic precursors.Investigational anabolic therapies for osteoporosis.Bone metastases: molecular mechanisms and novel therapeutic interventions.Antagonism of activin by activin chimeras.TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.Prevention and treatment of myeloma bone disease.

P2860

Q24633744-6383BD95-BC71-4E16-A374-FF703A24CB3B Q26798172-B431BE28-F811-4CE1-8759-E8866B3CA8B1 Q27342550-93959201-ADDA-41B6-8AEA-B75E190DD8C6 Q28512840-F4F3644D-6DE1-4325-A23A-77C072769C8E Q30438167-CD385296-1161-4912-94D5-5B6876F910AD Q33740176-9C433978-D75A-44ED-B147-2A55EE81F3C1 Q33786824-E17CB2E7-D41F-4889-AC07-4BB7D6543C4D Q33914768-4ABCE51E-5609-4B3F-9177-6D31146A8F69 Q34026190-8248C658-6AE6-4D21-A521-C1A38AAB63A7 Q34038854-1519F6B8-F9EB-4065-90F9-81DF75D1F0DF Q34418716-A7C875AC-337D-4504-A07F-80FE1C217D0E Q34442832-C295406A-784A-489C-8288-929B32D0BE93 Q34803626-67D21843-F3A7-4367-BFED-D6760856FA81 Q35035011-8CB88026-DE64-4124-A840-5E72BEB46A92 Q35148782-0E9B2A61-9ECA-4C74-B461-535237C03C4D Q35153096-4C7691D7-8CA9-4E26-8ACC-CE538F321D7D Q35233209-B947B6B4-1B73-4827-AA0F-36A0F7417DB5 Q35603116-B3756CB8-481A-4500-A31F-4E5E5C847AB9 Q35640712-FBEB1148-7B0E-42AC-BCCA-D958E56B34CD Q35744492-DDD94702-57C5-4D55-BD1D-60311DAE6F60 Q35754801-95DB0F00-AFF1-4909-A9E4-4280A6A63B8F Q35755200-844E3DD8-AD6E-49EC-AEEF-D21CD85DB6FE Q35786468-E0A7E0EC-0CE7-4F31-8D9F-8322BC538494 Q36132931-9E64AE3C-8D7B-4947-AADA-0D10FB66ADFC Q36254527-33E1929B-F20D-46AB-8EC8-CAC7D530B8E1 Q36256670-7D554664-66F4-4DC6-8B81-5A9EA1844DAA Q36445723-EAB39E18-200C-46CA-8BA8-501CB49DCFC6 Q36898276-B782B623-8DE3-4413-A676-0DFA4A1190A1 Q36919044-718C7F4A-F3DF-4ED6-8375-6B70ACDE53C6 Q36925346-5EF874A8-E291-48C5-A9DD-8883E60539B0 Q36968228-A0E788E2-1B5A-4713-A095-3A9E180EE3DB Q37214690-5C68E488-3F7A-4227-AEFD-3E9424372D61 Q37268461-724454AC-1655-418D-976C-5A4C962BF0F0 Q37337495-96407CAB-10CC-41AE-AFA0-625AC78E3876 Q37428593-A481541C-5AE0-488B-9115-B5C416547BF6 Q37772520-23D71458-CDB5-4F0A-8B2D-A89762AD1249 Q37785505-74600EE9-62D6-43CD-9331-55C471D43C4F Q37847427-2E826570-9660-41DE-97ED-A3C917837955 Q37900199-6DA98F51-3A66-4A46-932D-B5499572C48A Q38039879-189EF37D-7091-4728-A02D-8380049EA56C

P2860

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

http://www.wikidata.org/entity/Q36657509

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A soluble activin type IIA rec ...... d improves skeletal integrity.

@ast

A soluble activin type IIA rec ...... d improves skeletal integrity.

@en

type

label

A soluble activin type IIA rec ...... d improves skeletal integrity.

@ast

A soluble activin type IIA rec ...... d improves skeletal integrity.

@en

prefLabel

A soluble activin type IIA rec ...... d improves skeletal integrity.

@ast

A soluble activin type IIA rec ...... d improves skeletal integrity.

@en

P1433

Q36657509-0D12E57B-09ED-426E-9C61-CD8E488DC5C1

P1476

Q36657509-00A4C27B-BE69-49AA-B88A-5EC8DC3CAFD4

P2093

Q36657509-12A0716C-7ED3-4AAB-B49C-877FBA0A8886

Q36657509-26517A85-2C24-4134-A3DE-3B431DF423FB

Q36657509-36CE90F1-B9B8-4A0B-9D57-1A018A5A9CDF

Q36657509-495CDFB1-2E58-4208-901C-53EA652358BF

Q36657509-4C88E16A-7D6E-44B0-A690-37DC26D84105

Q36657509-697AFD56-DA14-4AF7-BE5C-08685E7BE205

Q36657509-8A7E14EE-5AF7-44F4-A610-D820A10BF7F2

Q36657509-8EDEDFB5-6F58-4304-B288-8A066BE86F1B

Q36657509-98D41CE7-B650-4B28-8443-67119C263A7F

Q36657509-9A1D9CA5-3466-427B-944E-CA749992D7A5

P2860

Q36657509-0954E27E-3276-41B5-BFA6-3C4BF72C3E0F

Q36657509-12A29CA8-41C3-4412-8FDE-8D97ABAD7120

Q36657509-19DB0847-7C5A-47E5-AD0D-4EC1720D5E54

Q36657509-2A88CF97-70A4-4737-A266-8B7B7E6952A2

Q36657509-2B2FF438-B166-4CD3-88F4-83B2533F657D

Q36657509-2EC3002B-7D53-459D-BA7C-76ED79ACA6E1

Q36657509-3314720B-4270-4105-8158-2C58B26A25B1

Q36657509-33B7DC62-1A2D-489C-87EB-BE6D7201E201

Q36657509-3B008874-6E20-4B6C-8D63-0FC77F77756F

Q36657509-568C3918-79EE-4BF1-A4DF-82EDD501A006

P304

Q36657509-6CAF1AD2-2B3E-4C05-8EE7-6E5B141CCF68

P31

Q36657509-C7D0A670-15CF-46F7-8921-5E3ADA3A11BB

P356

Q36657509-59AC32C7-C421-4AB7-BDD9-E622A06A2DE7

P407

Q36657509-6F6CA50A-3742-4EDA-AEFE-F931F9EC8EF5

P433

Q36657509-1EC8E553-2D78-4539-81F0-9A317F3A8659

P478

Q36657509-198E54E7-4B1C-490F-A06A-781004422C74

P50

Q36657509-540DE560-EDBE-45BB-961B-F1B02A802097

Q36657509-B254BD8D-0D29-440E-9BB2-EBD0249FE1C0

P577

Q36657509-96ACAA0E-939F-4B4B-91E8-F90501B32216

P5875

Q36657509-7540C702-91D3-4F0C-AC37-9DE7ECF195DF

P698

Q36657509-8E92F046-E773-4DB5-8DDC-5185E77B3D54

P932

Q36657509-2A44FBD7-BD24-4655-A530-409C54E6DE46

P356

PNAS.0711263105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A soluble activin type IIA rec ...... d improves skeletal integrity.

@en

P2093

Asya Grinberg

http://www.w3.org/2001/XMLSchema#string

Brendan Haigis

http://www.w3.org/2001/XMLSchema#string

Deanna Smith

http://www.w3.org/2001/XMLSchema#string

Eileen Pobre

http://www.w3.org/2001/XMLSchema#string

Eric D Werner

http://www.w3.org/2001/XMLSchema#string

Ernesto Canalis

http://www.w3.org/2001/XMLSchema#string

Jasbir Seehra

http://www.w3.org/2001/XMLSchema#string

Jeffrey Ucran

http://www.w3.org/2001/XMLSchema#string

Kathryn W Underwood

http://www.w3.org/2001/XMLSchema#string

Lisa Stadmeyer

http://www.w3.org/2001/XMLSchema#string

P2860

Betaglycan binds inhibin and can mediate functional antagonism of activin signalling

Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats

Skeletal overexpression of gremlin impairs bone formation and causes osteopenia

BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors

Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells

FSH directly regulates bone mass

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies.

P304

7082-7087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0711263105

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Ernesto Canalis

Mary L Bouxsein

P577

2008-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5391703

http://www.w3.org/2001/XMLSchema#string

P698

18460605

http://www.w3.org/2001/XMLSchema#string

P932

2383948

http://www.w3.org/2001/XMLSchema#string